Condition: Allergies · Sponsor: University Hospital, Strasbourg, France
Apple-birch pollen-food allergy syndrome is particularly common in Northern and Central Europe (70% of patients allergic to birch pollen), and classically induces an oral syndrome that impairs patients' quality of life. Current treatment is based on food avoidance. However, evidence of the efficacy of this treatment is limited (small numbers, lack of validation with a control group, absence of double-blind evaluation of the primary endpoint in a challenge test against placebo). The aim of oral immunotherapy with raw apple is to improve the management of allergic patients by enabling them to acquire tolerance to raw apple and other rosacea.
This description comes directly from the study's public registry record.
Anays PIOTIN, Dr · +33 03.69.55.00.49 · anays.piotin@chru-strasbourg.fr
Always discuss trial participation with your own doctor first.
| Hôpitaux Universitaires de Strasbourg | Strasbourg, France, France | Recruiting |
| Chu Jean Minjoz | Besançon, France | Not Yet Recruiting |
| Hopital François Mitterrand Chu Dijon | Dijon, France | Recruiting |
| Hopital Maison Blanche Chu Reims | Reims, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06771791